Clinical trials: Neurological Diseases
Rett Syndrome, RTT
Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
To evaluate the efficacy of cannabidiol oral solution (GWP42003-P, CBD-OS) in reducing symptom severity when compared with placebo, in participants with Rett syndrome.
- Trial name
- ARCH (NCT03848832)
- Testing
- GWP42003-P
- Where
- 26 sites in United States, Italy and 2 more
- Volunteers
- 29 people
- Sponsor
- Jazz Pharmaceuticals
Chronic Pain, Low Back Pain
Embodiment in Virtual Reality as a Telemedicine Digital Therapeutic for the Treatment of Chronic Shoulder Pain
Chronic shoulder pain is a common musculoskeletal pain condition that can have a profound impact on a sufferer's life and a large socioeconomic healthcare burden to society.
- Conditions
- Chronic Pain, Low Back Pain, Shoulder Pain
- Trial name
- NCT05375500
- Testing
- telemedicine digital therapeutic
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Karuna Labs Inc.
Arrythmia, Syncope
Arrhythmia Identification in Syncope Patients: ePatch® Versus 24h Holter
This study is a Multi-center, prospective, randomized, unblinded, two-arm study to assess if 7-days of cardiac monitoring using the ePatch Holter results in identification of more clinically actionable arrythmia for patients with…
- Trial name
- NCT06310707
- Testing
- ePatch ® Extended Wear Holter (EWH)
- Where
- 2 sites in France, Germany
- Volunteers
- 55 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Spinal Cord Injuries, Tetraplegia
Human Factors Validation Testing of the Wandercraft Personal Exoskeleton
The goal of this interventional, national, prospective, open and monocentric study is to demonstrate that a personal exoskeleton can be used by the intended users without serious use errors or problems, for the intended uses and…
- Conditions
- Spinal Cord Injuries, Tetraplegia, Paraplegia
- Trial name
- ExoUser (NCT06715631)
- Testing
- Hands-free exoskeleton
- Where
- France
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Wandercraft
Drug Resistant Partial Onset Seizure
A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures
A follow-on, two-year open-label extension study of ganaxolone as add-on therapy in adult patients with drug-resistant partial-onset seizures
- Trial name
- NCT02519439
- Testing
- ganaxolone
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Marinus Pharmaceuticals
Chronic Troublesome Sialorrhea, Parkinson's Disease
Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions
The objective of this study is to investigate the efficacy and safety of two different dose levels of NT 201 (75 U or 100 U per cycle), compared with placebo, in reducing the salivary flow rate, and the severity and frequency of…
- Conditions
- Chronic Troublesome Sialorrhea, Parkinson's Disease, Post-stroke, Traumatic Brain Injury
- Trial name
- SIAXI (NCT02091739)
- Testing
- IncobotulinumtoxinA (100 Units), IncobotulinumtoxinA (75 Units)
- Where
- 31 sites in Germany, Poland
- Volunteers
- 184 people
- Sponsor
- Merz Pharmaceuticals GmbH
Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis
A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017
This is a phase 1，randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects
- Conditions
- Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06980207
- Testing
- LY03017
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Polyneuropathies, Peripheral Nerve Injuries
Peripheral Physiological Measures as Determinants of Pain Risk
This study evaluates peripheral nervous system function using Multiple Excitability Measures (MEM) to obtain "electrophysiological pain phenotypes"
- Conditions
- Polyneuropathies, Peripheral Nerve Injuries, Peripheral Nervous System Diseases, Chemotherapy Effects
- Trial name
- DOLORiskWP51 (NCT02985294)
- Testing
- Multiple Excitability Measures of peripheral nerves
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Neuroscience Technologies SLP, Barcelona
Coronary Artery Disease, Angina Pectoris
Effect of Alirocumab(Proprotein Convertase Subtilisin/Kexin type9 Inhibitor) and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaques in Coronary Artery Disease Evaluated by Near-infrared Spectroscopy Intravascular Ultrasound
The purpose of this study is to verify whether additional administration of Alirocumab exerts a stronger stabilizing effect on the vulnerable plaque in CAD, compared with statin alone administration in patients receiving PCI.
- Trial name
- ANTARES (NCT03529253)
- Testing
- Alirocumab 75 MG/ML [Praluent]+ Rosuvastatin 10mg/daily, Rosuvastatin calcium10mg
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Kobe University
Hearing Loss
Evaluation of a New Noise Reduction Strategy in Hearing Aids
The goal of this exploratory interventional study is to evaluate a new hearing aid noise-reduction strategy in experienced hearing aid users, compared to currently available strategies.
- Trial name
- NCT06138665
- Testing
- Phonak Audeo Infinio Sphere, Hearing aid B, Hearing aid C
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Sonova AG
Symptomatic Vitreomacular Adhesion
A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion
The purpose of this study is to evaluate the superiority regarding vitreomacular adhesion (VMA) resolution of a single intravitreal injection of A01016 (Ocriplasmin) compared to sham-injection in subjects with symptomatic VMA.
- Trial name
- NCT01889251
- Testing
- Ocriplasmin
- Where
- Japan
- Volunteers
- 251 people
- Sponsor
- Alcon Research
Sleep Disorder
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness
The main purpose of this study is to evaluate the safety and tolerability of the drug ABT-652 given once daily to people with excessive daytime sleepiness.
- Trial name
- NCT01124851
- Testing
- ABT-652
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Abbott
Sciatica
Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants
The primary objective of the study is to determine the safety/tolerability profile, systemic PK behavior, and immunogenicity of single IV and SC administrations of BG00010 to sciatica participants.
- Trial name
- NCT00961766
- Testing
- BG00010 (Neublastin)
- Where
- Australia
- Volunteers
- 48 people
- Sponsor
- Biogen
Movement Disorders, Parkinson Disease
A Post-Market Study Evaluating the Safety of Infinity DBS System With MR Conditional Labeling
The Infinity MRI PMCF was conducted as an international, multicenter, observational, prospective, single-arm, post-market clinical follow-up (PMCF) study.
- Conditions
- Movement Disorders, Parkinson Disease, Essential Tremor, Tremor
- Trial name
- NCT03884231
- Testing
- Infinity DBS System with MR Conditional labelling
- Where
- 16 sites in United States, France and 3 more
- Volunteers
- 74 people
- Sponsor
- Abbott Medical Devices
Diabetic Neuropathic Pain
A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain
People with diabetes can, over time develop nerve damage throughout the body with symptoms such as pain, tingling, or numbness (loss of feeling) in the hands, arms, feet and legs.
- Trial name
- NCT01345045
- Testing
- ABT-639, pregabalin
- Where
- 35 sites in United States, Czechia and 3 more
- Volunteers
- 193 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Neuralgia,Postherpetic
Safety and Efficacy of Gabapentin in Postherpetic Neuralgia
Gabapentin and pregabalin are treatments for some types of neuropathic pain, including postherpetic neuralgia (PHN). However, these treatments usually need to be taken 3 times a day for effective pain control.
- Trial name
- NCT00636636
- Testing
- Gabapentin Extended Release tablets
- Where
- 39 sites in United States, Argentina and 1 more
- Volunteers
- 452 people
- Sponsor
- Depomed
Alzheimer's Type Dementia
A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia
The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with severe Alzheimer's disease.
- Trial name
- NCT01276353
- Testing
- E2020
- Where
- 11 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Eisai Inc.
Neuropathic Pain
Safety, Tolerability, and Pharmacokinetics of ASCT-83 in Healthy Adults
The goal of this clinical trial is to learn if ASCT-83 is safe and well-tolerated and measure how ASCT-83 is absorbed, distributed, and eliminated from the body over time. The study will be conducted in healthy adults.
- Trial name
- NCT07363395
- Testing
- ASCT-83
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Alcamena Stem Cell Therapeutics
Epilepsy
Safety, Tolerability, and Exploratory Efficacy of Adjunctive EQU-001 for Seizures in Adults With Epilepsy
This is a double-blind, placebo controlled, randomized study of dose-ranging safety, tolerability, exploratory efficacy of adjunctive EQU-001 for seizures using the continuous reassessment method in patients diagnosed with…
- Trial name
- NCT05063877
- Testing
- EQU-001
- Where
- 10 sites in United States, Israel
- Volunteers
- 43 people
- Sponsor
- Equilibre Biopharmaceuticals B.V.
Neuralgia, Postherpetic
Dose Ranging Trial to Determine the Safety and Efficacy of EMA401 in Patients With PHN
The study is a randomized, double blind, placebo-controlled, parallel-group comparison (two dose levels of EMA401 versus a placebo group), of safety and efficacy in patients with postherpetic neuralgia.
- Trial name
- NCT02426411
- Testing
- EMA401 200 mg, EMA401 600 mg
- Sponsor
- Spinifex Pharmaceuticals Pty Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.